

FACTOR IX (RECOMBINANT)

OTHER NAMES	Recombinant Factor 9, Factor IX, Benefix, BeneFIX® Coagulation Factor IX (Recombinant), Alprolix™, Rebinyn®
PRODUCT COMPOSITION	Product is formulated as a sterile, nonpyrogenic, lyophilized powder which has been manufactured by recombinant DNA technology. The concentration of Factor IX (IU) will vary depending on the lot number. Factor IX concentrate is cell free and therefore is administered without regard to patient ABO or Rh type.
INFORMED CONSENT	Not required
ALTERNATIVES	Non-blood Product: None
	Blood Product: None
DOSAGE	<ul style="list-style-type: none"> • Dosage and duration of treatment will depend on the patient factor deficiency and the circumstances necessitating the treatment • The manufacturer product monograph will provide specific dosage guidelines • Ordered as IU (international units) and a timed frequency (e.g. Q2h) • Transfusion Medicine (TM) will provide the dose requested $\pm 10\%$ depending on available vial sizes
ADMINISTRATION	<ul style="list-style-type: none"> • Reconstituted and filtered by TM and supplied to unit in a syringe • Product is best given immediately after preparation, MUST be within 3 hours of reconstitution • Should be inspected visually for particulate matter and discoloration prior to administration • Should be given IV direct push, recommended over 3 to 5 minutes – see product insert for specific administration rate guidelines • Flush tubing pre and post infusion with 0.9% NaCl <p>Administer the entire amount</p>
DIAGNOSTIC MONITORING	<p>Vital sign monitoring as per hospital policy for any blood, blood component and other related product. In the event of an immediate or suspected transfusion reaction, refer to hospital policy and procedures.</p> <ul style="list-style-type: none"> • Allergic / Anaphylactic reactions have been noted; it is suggested to remain with patient at least 5 minutes following administration
CLINICAL INDICATIONS	Factor IX is indicated for the control and prevention of bleeding episodes in patients with Hemophilia B (Christmas disease)
SPECIAL CONSIDERATIONS	<ul style="list-style-type: none"> • TM will need approximately 30 minutes preparation time • TM needs prompt notification of changes of both dosage and/or frequency • Factor IX concentrates have been associated with the development of thromboembolic complications and should be used with caution in patients with signs of fibrinolysis and DIC
STORAGE CONDITIONS	DO NOT REFRIGERATE AFTER RECONSTITUTION
REFERENCES	Review product monograph